|
|
News Breaks | | | | February 13, 2013 | | 11:55 EDT |  | SNTA, EZCH, JNY, ARRS, AZN | High option volume stocks: SNTA EZCH JNY ARRS AZN
| |
|
News For SNTA;EZCH;JNY;ARRS;AZN From The Last 14 Days Check below for free stories on SNTA;EZCH;JNY;ARRS;AZN the last two weeks. |
|
|
| May 22, 2013 | | 09:01 EDT |  | AZN | Par Pharmaceutical begins shipment of generic Atacand
 Subscribe for More Information | | | May 21, 2013 | | 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). | | | May 17, 2013 | | 10:36 EDT |  | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | | | 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. | | | May 16, 2013 | | 09:04 EDT |  | EZCH | Cisco results positive for semiconductors space, says Brean Capital
Subscribe for More Information | | | May 15, 2013 | | 09:47 EDT | | ARRS | Arris May volatility elevated into Q2 and outlook
Arris May call option implied volatility is at 51, June is at 27, August is at 28; compared to its 26-week average of 29 according to Track Data, suggesting larger near term price movement into the expected release of Q2 results today after the market close. | | | May 14, 2013 | | 11:44 EDT | | EZCH | Options with decreasing implied volatility: GRPN MAKO GMCR EZCH SGMO
| | | 11:41 EDT | | JNY | High option volume stocks: DANG RLGY JNY TTWO OPTR
| | | 08:06 EDT | | JNY | BofA/Merrill's retail analysts hold an analyst/industry conference call
Global Retail Team discusses key global athletic themes including industry trends, sourcing costs outlook and favorite investment ideas on an Analyst/Industry conference call. Relevant covered companies COLM, COST, DKS, FINL, FL, GES, JNY, NKE, PVH, RL, TGT, UA and WMT may be included on the Analyst/Industry conference call to be held on May 14 at 10 am. | | | 07:24 EDT | | AZN | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | | May 13, 2013 | | 16:53 EDT |  | AZN | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link | | | 15:55 EDT | | AZN | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information | | | 11:55 EDT | | EZCH | SodaStream, EZchip aren't good targets for short traders, Globes columnist says
SodaStream (SODA) is in the midst of squeezing out short traders, while EZchip Semiconductor (EZCH) is in the beginning of doing so, Israeli analyst Shlomi Cohen wrote in Globes. Short players in both stocks should abandon their positions, as SodaStream's strategy can change consumer habits,and EZchip's conference call was "full of good news," the analyst wrote. Ezchip reported that it expects to reach deals with top tier customers this year, and is developing NPS processors that it says could be "game changers," Cohen noted. Reference Link | | | 11:07 EDT | | EZCH | Options with decreasing implied volatility: EZCH MM MAKO MBI FOSL
| | | 10:09 EDT |  | EZCH | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 06:21 EDT | | EZCH | EZchip downgraded to Equal Weight from Overweight at Barclays
Price target lowered to $30 from $38. | | | May 10, 2013 | | 14:12 EDT | | ARRS | Arris to host a conference call
Management provides 2Q13 financial guidance and overall 2013 outlook on a conference call to be held on May 15 at 6 pm .Webcast Link | | | 12:32 EDT | | SNTA | Options with increasing implied volatility: SNTA BKS FIO QIHU VMED
| | | 11:48 EDT | | AZN | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | 11:27 EDT | | EZCH | Options with decreasing implied volatility: MBI SGMO ALGN GMCR EZCH
| | |
|
|
|
|
|
|
